

# GREECE

Number of new cases

**65 703**

Number of deaths

**32 385**

Number of prevalent cases (5-year)

**190 598**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	5 064 410	5 252 231	10 316 641
<b>Incidence*</b>			
Number of new cancer cases	36 564	29 139	65 703
Age-standardized incidence rate	295.0	231.3	258.7
Risk of developing cancer before the age of 75 years (cum. risk %)	30.2	22.5	26.1
Top 3 leading cancers (ranked by cases)**	Prostate Lung Colorectum	Breast Colorectum Lung	Breast Lung Colorectum
<b>Mortality*</b>			
Number of cancer deaths	19 120	13 265	32 385
Age-standardized mortality rate	129.7	76.4	100.6
Risk of dying from cancer before the age of 75 years (cum. risk %)	13.6	7.9	10.6
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Prostate	Breast Lung Colorectum	Lung Colorectum Breast
<b>Prevalence*</b>			
5-year prevalent cases	98 961	91 637	190 598



## Top 5 most frequent cancers\*\*


**Males**



Rank	Cancer site	Number of cases	Percent
1st	Prostate	7 036	19.2%
2nd	Lung	6 357	17.4%
3rd	Colorectum	4 346	11.9%
4th	Bladder	4 257	11.6%
5th	Kidney	1 247	3.4%
-	Others	13 321	36.4%

Number of new cases in 2022, males, all ages


**Females**



Rank	Cancer site	Number of cases	Percent
1st	Breast	8 987	30.8%
2nd	Colorectum	3 513	12.1%
3rd	Lung	2 226	7.6%
4th	Corpus uteri	1 950	6.7%
5th	Pancreas	1 080	3.7%
-	Others	11 383	39.1%

Number of new cases in 2022, females, all ages

**Both sexes**



Rank	Cancer site	Number of cases	Percent
1st	Breast	8 987	13.7%
2nd	Lung	8 583	13.1%
3rd	Colorectum	7 859	12.0%
4th	Prostate	7 036	10.7%
5th	Bladder	5 122	7.8%
-	Others	28 116	42.8%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	8 987	1	13.7	8.7	2 431	3	7.5	1.6	36 536	19.2
Lung	8 583	2	13.1	4.0	7 156	1	22.1	3.1	10 014	5.3
Colorectum	7 859	3	12.0	3.2	3 764	2	11.6	1.1	23 679	12.4
Prostate	7 036	4	10.7	7.1	1 945	5	6.0	0.71	27 358	14.4
Bladder	5 122	5	7.8	2.3	1 554	6	4.8	0.40	17 121	9.0
Pancreas	2 305	6	3.5	0.93	2 180	4	6.7	0.83	1 837	0.96
Corpus uteri	1 950	7	3.0	2.2	407	15	1.3	0.29	7 899	4.1
Leukaemia	1 938	8	3.0	0.81	1 357	8	4.2	0.38	5 493	2.9
Kidney	1 875	9	2.9	0.95	684	11	2.1	0.22	5 949	3.1
Stomach	1 871	10	2.8	0.73	1 252	9	3.9	0.42	2 397	1.3
Liver	1 669	11	2.5	0.61	1 468	7	4.5	0.47	1 700	0.89
NHL	1 663	12	2.5	0.84	666	13	2.1	0.21	5 428	2.8
Melanoma	1 458	13	2.2	0.77	308	17	0.95	0.11	5 546	2.9
Brain CNS	1 306	14	2.0	0.64	1 036	10	3.2	0.48	5 040	2.6
Thyroid	1 025	15	1.6	0.65	87	23	0.27	0.03	3 904	2.0
Ovary	983	16	1.5	0.95	681	12	2.1	0.52	2 883	1.5
Larynx	849	17	1.3	0.44	363	16	1.1	0.14	2 878	1.5
Multiple myeloma	763	18	1.2	0.33	579	14	1.8	0.18	2 154	1.1
Lip, oral cavity	688	19	1.0	0.31	250	19	0.77	0.09	2 187	1.1
Cervix uteri	473	20	0.72	0.55	260	18	0.80	0.24	1 655	0.87
Testis	446	21	0.68	0.68	26	30	0.08	0.03	1 996	1.0
Oesophagus	252	22	0.38	0.11	228	20	0.70	0.09	310	0.16
Hodgkin lymphoma	213	23	0.32	0.15	37	29	0.11	0.02	836	0.44
Vulva	205	24	0.31	0.12	91	22	0.28	0.03	593	0.31
Nasopharynx	189	25	0.29	0.11	100	21	0.31	0.05	616	0.32
Penis	167	26	0.25	0.14	43	27	0.13	0.03	532	0.28
Salivary glands	130	27	0.20	0.05	68	25	0.21	0.02	388	0.20
Mesothelioma	87	28	0.13	0.04	72	24	0.22	0.03	101	0.05
Gallbladder	83	29	0.13	0.04	54	26	0.17	0.02	102	0.05
Oropharynx	69	30	0.11	0.04	41	28	0.13	0.02	214	0.11
Kaposi sarcoma	44	31	0.07	0.01	9	32	0.03	0.00	129	0.07
Hypopharynx	23	32	0.04	0.01	13	31	0.04	0.01	46	0.02
<b>All cancers</b>	<b>65 703</b>	-	-	<b>26.1</b>	<b>32 385</b>	-	-	<b>10.6</b>	<b>190 598</b>	-
<b>All cancers excl. NMSC</b>	<b>63 176</b>	-	-	<b>25.8</b>	<b>32 223</b>	-	-	<b>10.6</b>	<b>182 531</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** No data  
**Method:** Estimated from national mortality estimates by modelling, using mortality:incidence ratios derived from cancer registry data in neighbouring countries

### Mortality

**Country-specific data source:** National (WHO)  
**Method:** National rates projected to 2022

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

